生物制剂治疗银屑病诱发特应性皮炎的研究进展  

Research Progress of Atopic Dermatitis Induced By Biologics on The Treatment of Psoriasis

作　　者：唐欣[1] 郑旭宇 李倩[1] 周翠 胡玉莲 王萍[1] 黄琨[1] TANG Xin;ZHENG Xuyu;LI Qian;ZHOU Cui;HU Yulian;WANG Ping;HUANG Kun(Department of Dermatology,the First Afiliated Hospital of Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院皮肤科,重庆400016

出　　处：《中国皮肤性病学杂志》2023年第2期231-234,共4页The Chinese Journal of Dermatovenereology

基　　金：国家自然科学基金资助项目(81972942);重庆市科卫联合医学科研项目(2020FYYX017)。

摘　　要：银屑病是一种常见的慢性、炎症性、系统性疾病,生物制剂已成为治疗中重度和难治性银屑病的重要手段。特应性皮炎作为一种与银屑病免疫机制相反的慢性炎症性皮肤病,发生在接受生物制剂治疗的银屑病患者中的报道逐渐增多,其机制可能与免疫漂移、微生物定植、皮肤屏障破坏及遗传等因素有关。患者既往的特应性病史、IgE水平升高、血嗜酸性粒细胞增多等是发病的共同因素。治疗上需根据银屑病及特应性皮炎的严重程度综合选择最佳治疗方案。Psoriasis is a common chronic, inflammatory and systemic disease, and biological agents have become an important treatment for moderate to severe psoriasis.Atopic dermatitis, as a chronic inflammatory skin disease whose immune mechanism is opposite to psoriasis, has been reported to occur in patients with psoriasis treated with biological agents. The mechanism may be related to immune drifting, microbial colonization, skin barrier destruction, and genetic factors. The history of atopic diseases, elevated IgE levels, and blood eosinophils might result in atopic dermatitis.The treatment should be selected according to the severity of psoriasis and atopic dermatitis.

关 键 词：银屑病 生物制剂 特应性皮炎 

分 类 号：R758.63[医药卫生—皮肤病学与性病学] R758.2[医药卫生—临床医学]